Clarivate Plc (CLVT) AI Stock Analysis

Clarivate Plc operates as an information services and analytics company providing structured insights and analytics for the discovery, protection, and commercialization of scientific research, innovations, and brands globally. Its portfolio includes the Web of Science platform alongside tools such as InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. For life sciences, Clarivate provides Cortellis and Newport Integrity for research support and market intelligence. Its Derwent suite includes Derwent Innovation, Techstreet, and IP Professional Services for patent and novelty assessments. In addition, CompuMark delivers trademark screening, while MarkMonitor manages and protects online brand presence.

Clarivate achieved a 5-year revenue CAGR of 14.4% between FY2020 and FY2025, with revenue peaking at $2.66B in FY2022 before declining to $2.63B in FY2023, $2.56B in FY2024, and $2.46B in FY2025. Gross margin was 66.0% in FY2025, while operating margin improved to 2.9% from -10.8% in FY2024 and -147.6% in FY2022. Net loss narrowed from -$3.96B in FY2022 to -$201.1M in FY2025. For the trailing twelve months, revenue was $2.41B with an operating margin of 6.1% and a profit margin of -13.8%. In the latest quarter ended June 30, 2026, quarterly revenue fell 5.5% year-over-year.

As of June 30, 2026, Clarivate held $217.7M in cash and short-term investments against $4.26B in total debt, resulting in net debt of $4.04B. Shareholders' equity was $4.54B and total assets were $10.49B, with a debt-to-equity ratio of 0.94 and a current ratio of 0.85. In FY2025, operating cash flow reached $628.5M and free cash flow was $365.3M. Cash usage during FY2025 included $263.2M in capital expenditures and $224.5M in share buybacks.

At $1.77 per share, Clarivate has a market cap of $1.13B and an enterprise value of $5.21B. CLVT trades at a forward P/E of 2.6x, an EV/EBITDA of 7.8x, and a price-to-sales ratio of 0.5x. Each of these multiples trades below the median of its US-listed Technology peers, which stands at 18.8x forward P/E, 16.6x EV/EBITDA, and 2.8x price-to-sales. Over the past year, CLVT fell 50.1%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock dropped 92.1% against an 83.0% gain for SPY.

Wall Street coverage includes 2 Strong Buy, 5 Hold, and 1 Sell ratings. The mean price target is $2.97, representing a 67.6% premium over the last close of $1.77. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $0.72 on $2.21B in revenue. For the following fiscal year, 3 analysts project EPS of $0.78 with revenue falling 8.7% to $2.02B. Clarivate has beaten EPS estimates in 4 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of Clarivate Plc (CLVT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CLVT income statement, CLVT balance sheet, CLVT key metrics, CLVT analyst forecast, CLVT chart. See the CLVT stock overview for the latest quote and news.